GET DAILY SIGNALSAllogene Therapeutics (ALLO) Q3 2026 Earnings: Cash Position and Pipeline Focus Take Center Stage
Key Takeaways
- Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, roughly in line with Wall Street's consensus estimate of a loss of about $0.15 per share.
- Collaboration revenue was $0 for the quarter, consistent with the company's status as a clinical-stage biotechnology firm with no approved products.
- Research and development (R&D) expenses rose to $41.9 million from $31.2 million a year earlier, reflecting heavier investment across its clinical pipeline.
- Cash, cash equivalents, and investments totaled $388.9 million as of September 30, 2026, supporting a projected cash runway into 2029.
- The company reiterated full-year 2026 GAAP (Generally Accepted Accounting Principles) operating expense guidance of approximately $225 million, including roughly $35 million in non-cash stock-based compensation.
- For more detail on Allogene, readers can review Major News, Today's Price Move, Price Targets, and Forecast on dedicated analysis pages.
- Investors interested in automated trading strategies can also explore Trending AI Robots for additional market insight.
Why These Numbers Matter for a Pre-Revenue Biotech
Allogene Therapeutics is a clinical-stage immuno-oncology company focused on developing off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases. Without commercial products, its quarterly results center on cash burn, spending discipline, and clinical advancement rather than top-line revenue. I pay close attention to R&D outlays and the cash balance because they indicate how long the firm can advance its programs before seeking more capital. With key data readouts on the horizon for its lead candidate and an expanding autoimmune effort, this quarter provided a useful snapshot of financial staying power and execution pace ahead of a potentially active 2027.
Quarterly Results in Detail
Allogene posted a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, compared with a net loss of $41.4 million, or $0.19 per share, in the year-earlier period. The total loss grew, yet the per-share amount improved as the weighted-average share count increased to 346.1 million from 222.0 million. The outcome aligned closely with analyst expectations of roughly a $0.15 per-share loss, and collaboration revenue remained at zero, matching the consensus view of no revenue.
R&D expenses climbed to $41.9 million from $31.2 million year over year, while general and administrative expenses eased to $12.9 million from $13.7 million. Total operating expenses reached $54.8 million, up from $44.9 million. The company finished the quarter with $388.9 million in cash, cash equivalents, and investments and reaffirmed its full-year 2026 GAAP operating expense guidance of about $225 million, which includes roughly $35 million in non-cash stock-based compensation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Shares of ALLO declined about 9% in the session after the release. The move seemed driven by the larger absolute loss, increased R&D spending, and typical investor caution around cash burn at a pre-revenue biotech. Although the per-share result met expectations, attention stayed on milestone risk and the path to upcoming clinical catalysts rather than the quarterly loss alone. Sentiment appears measured, with valuation still tied to the success of pivotal programs.
Key Items to Follow Going Forward
The most critical factor for ALLO is clinical progress rather than any single quarter’s loss. The pivotal ALPHA3 trial of cema-cel in earlier-line large B-cell lymphoma is set to deliver an update in mid-2027, with full enrollment expected by the end of that year; this readout could prove pivotal for the stock.
Another near-term focus is the autoimmune program. Updated data from the ALLO-329 trial, testing a dual CD19/CD70 CAR T approach in multiple autoimmune conditions, is scheduled for presentation on November 9, 2026. Investors will look for biomarker and early response signals, given the sizable market potential.
Capital management will also stay important. With roughly $388.9 million in cash and a runway into 2029, Allogene has solid flexibility, though rising R&D costs from trial expansion will require careful balancing against any future financing needs. Regulatory milestones, enrollment rates across sites, and possible partnerships remain worth tracking.
AI Tools in My Biotech Research Workflow
When evaluating names like this, I often turn to Tickeron’s AI Screener to quickly filter peers by fundamentals, technical patterns, and volatility. It helps me place quarterly updates in broader context without spending hours on manual screens. I find the customizable filters particularly useful for staying organized ahead of catalyst dates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALLO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALLO turned positive on November 04, 2026. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALLO's RSI Oscillator exited the oversold zone, 37 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 76 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALLO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.863) is normal, around the industry mean (2.904). P/E Ratio (-1.652) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology
Advertisement